Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam

Reuters

Dec 09, 2025

Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam

Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590349843"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590349843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590349843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590349843","market":"nz","top_or_hot":-1,"title":"Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8L61ty:1","article_id":"2590349843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590349843","pubTimestamp":1765285273,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lee's Pharmaceutical Holdings Limited is acquiring the Staccato One Breath Technology  platform and related assets, including global rights as licensor and manufacturer for Staccato alprazolam, as part of an expanded partnership with UCB. The Staccato OBT platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00950":"李氏大药厂"},"translate_title":"李氏制药收购Staccato One Breath技术及阿普唑仑全球权益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":0.9},"content_text":"Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    \n\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}